Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C thr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/9/581 |
| _version_ | 1797580692940390400 |
|---|---|
| author | John Paul Yun Philip Q. Ding Aastha Dolley Winson Y. Cheung |
| author_facet | John Paul Yun Philip Q. Ding Aastha Dolley Winson Y. Cheung |
| author_sort | John Paul Yun |
| collection | DOAJ |
| description | The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada’s Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (<i>n</i> = 164) or disease progression (<i>n</i> = 133). Multivariable cox regression showed that age, province of residence, blast counts, antibiotic prophylaxis, and number of dose reductions and delays were not significantly associated with overall and progression-free survival. DEC-C is a promising alternative to parenteral hypomethylating agent therapy, and it likely addresses an important unmet need for effective and convenient therapies in this setting. |
| first_indexed | 2024-03-10T22:53:30Z |
| format | Article |
| id | doaj.art-b48668b1455c4f7c8dd47a3180a53e66 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T22:53:30Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-b48668b1455c4f7c8dd47a3180a53e662023-11-19T10:10:48ZengMDPI AGCurrent Oncology1198-00521718-77292023-08-013098005801810.3390/curroncol30090581Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in CanadaJohn Paul Yun0Philip Q. Ding1Aastha Dolley2Winson Y. Cheung3Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaOncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaTaiho Pharma Canada, Inc., Oakville, ON L6H 5R7, CanadaOncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, CanadaThe management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada’s Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (<i>n</i> = 164) or disease progression (<i>n</i> = 133). Multivariable cox regression showed that age, province of residence, blast counts, antibiotic prophylaxis, and number of dose reductions and delays were not significantly associated with overall and progression-free survival. DEC-C is a promising alternative to parenteral hypomethylating agent therapy, and it likely addresses an important unmet need for effective and convenient therapies in this setting.https://www.mdpi.com/1718-7729/30/9/581myelodysplastic syndromechronic myelomonocytic leukemiareal-world evidencehypomethylating agentstreatment patternspatient support programs |
| spellingShingle | John Paul Yun Philip Q. Ding Aastha Dolley Winson Y. Cheung Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada Current Oncology myelodysplastic syndrome chronic myelomonocytic leukemia real-world evidence hypomethylating agents treatment patterns patient support programs |
| title | Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada |
| title_full | Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada |
| title_fullStr | Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada |
| title_full_unstemmed | Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada |
| title_short | Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada |
| title_sort | decitabine cedazuridine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia in canada |
| topic | myelodysplastic syndrome chronic myelomonocytic leukemia real-world evidence hypomethylating agents treatment patterns patient support programs |
| url | https://www.mdpi.com/1718-7729/30/9/581 |
| work_keys_str_mv | AT johnpaulyun decitabinecedazuridineinthemanagementofmyelodysplasticsyndromeandchronicmyelomonocyticleukemiaincanada AT philipqding decitabinecedazuridineinthemanagementofmyelodysplasticsyndromeandchronicmyelomonocyticleukemiaincanada AT aasthadolley decitabinecedazuridineinthemanagementofmyelodysplasticsyndromeandchronicmyelomonocyticleukemiaincanada AT winsonycheung decitabinecedazuridineinthemanagementofmyelodysplasticsyndromeandchronicmyelomonocyticleukemiaincanada |